Molecular Devices Completes Acquisition of Axon Instruments
Molecular Devices of Sunnyvale, Calif., announced on July 1 that its acquisition of Australia-based Axon Instruments is complete.
The deal, in which Molecular Devices is paying approximately $68 million of cash in exchange for all outstanding shares of Axon, was originally announced on March 21. Molecular Devices said that as a result of the acquisition, it received approximately $26 million in cash that had been on Axon’s balance sheet.
Axon offers two high-throughput cell-based screening platforms: the ImageXpress automated cellular imaging and analysis system, and the PatchXpress automated parallel patch-clamp system. The products are expected to complement two of Molecular Devices’ suite of cell-based assay offerings: the Discovery-1 high-content imaging system and the IonWorks HT electrophysiology system (for more, see Inside Bioassays, 4/20/2004).
Upstate and Evident to Manufacture Quantum Dot Products
Evident Technologies and Upstate said last week they will produce quantum dot-based products for the life science industry.
Upstate, based in Charlottesville, Va., will use EviTag fluorescent nanocrystals from Troy, NY-based Evident to produce new quantum dot-based conjugates that offer increased photostability and multicolor fluorescence. Fluorescent nanocrystals have a wide variety of cell biology applications, including highly stable fluorescent tags for cell-based screening.
The companies did not disclose financial terms of the agreement.
Serologicals Acquires AltaGen Biosciences and Sierra BioSource Subsidiary
Serologicals Corporation will acquire AltaGen Biosciences and its subsidiary, Sierra BioSource, the Atlanta, Ga.-based company said last week.
Morgan Hill, Calif.-based AltaGen and Sierra BioSource provide contract research and development services in the areas of cellular and molecular biology, immunology, animal pharmacology, monoclonal antibodies and recombinant proteins, and specialty cell culture development and purification.
The acquisition, which Serologicals hopes to close by the end of the third quarter, will enable it “to more broadly address the cell culture market,” according to a company statement.
Serologicals and Sierra have been collaborating on research projects since 2002.